Reuters -- Targacept Inc said its experimental depression drug, TC-5214, that was being tested as an augmentation treatment for major depressive disorder, met all the goals of a mid-stage trial.
Reuters -- Targacept Inc said its experimental depression drug, TC-5214, that was being tested as an augmentation treatment for major depressive disorder, met all the goals of a mid-stage trial.
